Azithromycin treats diffuse panbronchiolitis by targeting T cells via inhibition of mTOR pathway

Azithromycin (AZM), that is a macrolide antibiotic, has been found to treat diffuse panbronchiolitis (DPB) effectively. However, the mechanism of action underlying the therapeutic effects remains unclear. We selected 64 patients with DPB from 305 patients who were diagnosed with DPB at the outpatient clinic in Shanghai Pulmonary Hospital from Jan 2010 to Oct 2014. The primary PBLs, CD4 + T cells, and Jurkat T cells were treated with AZM or erythromycin (EM), and the effects of AZM and EM on IL-17A and CXCL-2 production, proliferation, apoptosis and autophagy were evaluated. AZM and EM significantly inhibited IL-17A and CXCL-2 production in patients' PBLs (all P < 0.05). AZM significantly inhibited proliferation and promoted apoptosis of T cells from DPB patients. AZM can enhance autophagosome formation of T cells by suppressing S6RP phosphorylation, which is a downstream target of mTOR pathway (all P < 0.05). AZM and EM significantly decreased secreted IL-17A levels (P < 0.05) in the primary CD4 + T cells of patients with DPB. AZM may treat DPB patients by targeting cytokine production, proliferation, apoptosis and autophagy of T cell. The mechanism of therapeutic effects of AZM on DPB may be associated with a specific inhibition of mTOR pathway in the T lymphocytes.

Diffuse panbronchiolitis research in MEDLINE (1969-2017): Report of a bibliometric analysis

BACKGROUND

Given the well documented and undesired impact of diffuse panbronchiolitis (DPB), there is a need to create a statistical inventory of research output on DPB. The aim of this study was to identify and analyze different trends in publication over time, with technological additions.

METHODS

Articles indexed in MEDLINE regarding DPB were retrieved using PubMed. Citation results were categorized by article type, year of publication, language, and country.

RESULTS

A total of 657 publications, published between 1969 and 2017 were retrieved from PubMed; the year with the highest number of articles published was 1992 (n = 32). Japan accounted for 68.34% (n = 449) publications, followed by the United States of America (USA; 6.70%, n = 44) and China (5.48%, n = 36). English (n = 401) was the most commonly used language in the publications, followed by Japanese (n = 223) and Chinese (n = 16). Articles were published in 218 different journals; The Japanese Journal of Thoracic Diseases published the maximum number of articles, accounting for 13.7% (n = 90) citations. Sugiyama Y was the most productive author and contributed to 12 publications.

CONCLUSIONS

This was the first bibliometric analysis of DPB. Between 1991 and 2000, the number of publications on DPB literature reached a peak, and although the frequency of publication has decreased recently, the quantity of DPB research during the past 48 years is adequate and satisfactory. Overall, the publications on DPB have undergone exponential growth over the last 30 years.

Azithromycin for the Prevention of COPD Exacerbations: The Good, Bad, and Ugly

Long-term azithromycin therapy has been shown to reduce exacerbations of chronic obstructive pulmonary disease (COPD), and is recommended by recent society guidelines for use in COPD patients who are at risk for recurrent exacerbations. However, concerns about adverse effects have limited its widespread adoption. Physicians deciding whether to use long-term azithromycin therapy must weigh each patient's individual risk of cardiovascular complications and both the individual and population impact of macrolide resistance against the expected benefit. This review will summarize evidence on the effectiveness and safety of chronic azithromycin for the prevention of COPD exacerbations.